Intellia Therapeutics, Inc. - Common Stock (NTLA)

CRISPR Therapeutics AG (NASDAQCRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. NASDAQ: VRTXNASDAQVRTX)

Intellia Therapeutics, Inc. (NASDAQNTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF). CF is a genetic disease caused by mutations in the CFTR gene, leading to the accumulation of thick mucus in the lungs, digestive systems and other organs. CF can result in life-threatening infections, respiratory failure and other serious complications.

The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.

Voyager Therapeutics Inc. (NASDAQVYGR) is a biotech in the medical sector that specializes in gene therapy for neurological diseases. Its shares took

Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal

On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQVRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for

Collaboration combines Intellia’s leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron’s proprietary antibody-targeted viral vector delivery technologies to jointly advance in vivo programs outside of the liver for neurological and muscular diseases

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors.

According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk.

Mid-cap land has long been regarded as the ‘sweet spot’ for equity investors. Here are three mid-caps Wall Street sees as two-baggers over the next 12 months.

Palm Beach, FL – June 29, 2021 – Glioblastoma multiforme (GBM) is one of the areas where the research & development investments are high and where global studies are growing. Everyone is looking to solve the problem. GBM, a fast-growing and aggressive brain tumor, is a devastating brain cancer that can result in death in six months or less, if untreated; hence, it is imperative to seek expert neuro-oncological and neurosurgical care immediately, as this can impact overall survival. Brain and other nervous system cancer is the 10th leading cause of death for men and women.  Globally, over 241,000 people die each year as a result of brain or nervous system cancer, with GBM being the most common form of the disease. According to iHealthcareAnaylist report, said that: “GBM has an incidence of two to three per 100,000 adults per year, and accounts for 52 percent of all primary brain tumors. Glioblastoma multiforme (GBM) is the most common and deadly brain tumor in adults. The incidence of GBM in the USA and Europe is 2–3 per 100,000. By definition, an orphan disease is one affecting 200,000 persons in the USA (one in every 1,500). In Europe, the definition is a bit narrower, with fewer than five in 10,000 (one in every 2,000) people affected.”  The report said that: “ The global Glioblastoma multiforme (GBM) drugs market is projected to reach nearly $1.8 billion by 2027, expanding at a CAGR of 12.8% during the forecast period, driven by rising geriatric population, growing incidence cases and rich clinical pipeline of new products. Glioblastoma is the most common primary malignant form of brain cancer. Despite technological advances in surgery and radio-chemotherapy, glioblastoma remains largely resistant to treatment. “    Active biotech and pharma companies in the markets this week include CNS Pharmaceuticals, Inc. (NASDAQCNSP), Intellia Therapeutics, Inc. NASDAQ: NTLANASDAQNTLA)(NASDAQ: AVXLNASDAQAVXL, Bristol Myers Squibb (NYSE: BMYNYSE), Clovis Oncology, Inc. (NASDAQ: CLVSCLVS).

Blackstone (NYSEBX) announced today that funds managed by Blackstone Life Sciences have committed $250 million towards the launch of a new autologous and allogeneic universal chimeric antigen receptor (CAR) T-cell therapy company, along with Intellia Therapeutics, Inc. NASDAQ: NTLANASDAQNTLA)